Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

July 24, 2019

Developments

Zenabis outperforms cannabis design capacity by 41% in June

Zenabis Global (TSX:ZENA) reported that its cultivation output in June 2019 was 756 kg of dried cannabis, which represents a 40.8% outperformance relative to design capacity, or a performance ratio of 40.8%. June 2019...

July 24, 2019

Developments

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

Chiasma (NASDAQ:CHMA) reported positive top-line Phase 3 data from a pivotal trial evaluating its octreotide candidate, conditionally trade-named Mycapssa, for the treatment of acromegaly. Acromegaly is caused by the...

July 23, 2019

Markets

Stifel cuts Viveve Medical to hold; PT to $1 from $3

Stifel downgraded Viveve Medical (NASDAQ:VIVE) to “hold” from “buy” and lowered its price target to $1 from $3 after the company’s LIBERATE-International trial for stress urinary incontinence (SUI) missed its primary...

July 23, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Developments

Intec Parkinson’s disease candidate misses primary endpoint in Phase 3 trial

Intec Pharma (NASDAQ:NTEC) reported that its Accordion Pill carbidopa/levodopa (AP-CD/LD) failed to meet its primary endpoint in a Phase 3 trial for Parkinson’s disease (PD). Intec’s extended release AP-CD/LD failed to...

July 22, 2019

Developments

Theravance reports new Phase 2 data for ampreloxetine

Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH). nOH is characterized by a fall in systolic or diastolic blood...

July 22, 2019

Developments

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

PharmaCyte Biotech (OTCQB:PMCB) entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes, with the...

July 22, 2019

Developments

Zenabis arranges $10-million of non-dilutive financing in supply pact with Starseed Medicinal

Zenabis Global (TSX:ZENA) entered into an agreement whereby Starseed Medicinal would advance $10-million to Zenabis in September 2019 in return for dried cannabis flower and trim from Zenabis. Under the accord, Zenabis...

July 22, 2019

Markets

WB starts Change Healthcare at OP

William Blair launched coverage of Change Healthcare (NASDAQ:CHNG) with an “outperform” rating. The stock closed at $13.50 on July 19. Change Healthcare is a leading healthcare technology platform provider, offering...

July 22, 2019

Developments

Anavex reports gut microbiota linked to improved ANAVEX2-73 response

Anavex Life Sciences (NASDAQ:AVXL) reported that Alzheimer’s disease (AD) patients with high levels of two gut microbiota families had an improved response to ANAVEX2-73. ANAVEX2-73 is an orally-administered liquid...

July 19, 2019

Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...

July 19, 2019

Dawson James starts Anavex at buy: PT $16

Zenabis outperforms cannabis design capacity by 41% in June

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

Stifel cuts Viveve Medical to hold; PT to $1 from $3

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

Intec Parkinson’s disease candidate misses primary endpoint in Phase 3 trial

Theravance reports new Phase 2 data for ampreloxetine

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

Zenabis arranges $10-million of non-dilutive financing in supply pact with Starseed Medicinal

WB starts Change Healthcare at OP

Anavex reports gut microbiota linked to improved ANAVEX2-73 response

Aridis Pharma gets EMA orphan drug designation for CF drug

General

More